Abstract:Objective: Engineered immune cells (e.g., therapeutic T cells) provide a revolutionary approach to combat cancer. Certain activated immune cells can exquisitely sense and respond to the tumor microenvironment. Here, we propose a paradigm based on engineering macrophages to allow selective intercellular drug delivery and augmentation of antitumor activities by hijacking tumor microtube networks. Methods: Macrophages were engineered via anchoring lipopolysaccharides on the plasma membrane (LM). The tumor tropism of LM encapsulating doxorubicin (LM-Dox) was monitored by a real-time cell migration assay and small animal in vivo imaging. Monocyte chemoattractant protein-1 (CCL2) was measured by quantitative PCR and ELISA. Intercellular conduit formation was characterized by confocal laser scanning microscopy and scanning electron microscopy. LM-Dox activation of tumor-associated macrophages to release TNF-alpha was evaluated by western blot and immunofluorescence assays. The potential therapeutic effects of LM-Dox in a 3D tumor-immune model and a murine orthotopic lung cancer model were tested. Results: LM-Dox exhibited tumor tropism in response to CCL2 produced by A549 lung tumor cells and lung tumor tissues resulting in a remarkably higher amount of tumor accumulation than the case of Lipo-Dox (similar to 4-fold). Intriguingly, LM-Dox accumulated at tumor sites hijacked the established tumor microtube networks and even stimulated microtube formation with tumor cells but not with normal cells to enable selective and rapid transport of the drug to tumor cells. Simultaneously, LM-Dox induced secretion of TNF-alpha in tumor-associated macrophages, which increased the antitumor activity of Dox. Thus, LM-Dox increased the inhibitory effects on tumor growth and metastasis in a mouse orthotopic lung cancer model and minimized the side effects of Dox-induced tumor invasion. Conclusion: Lipopolysaccharide-anchored macrophages that can hijack tumor microtube networks for selective drug transport may serve as versatile bioactive carriers of anticancer drugs. In the clinical context, these engineered microphages represent a personalized medicine approach that can be translated into potential use of patient-derived monocytes/macrophages for drug delivery by means of cell-to-cell communication.

Leveraging Nanodrug Delivery System for Simultaneously Targeting Tumor Cells and M2 Tumor-Associated Macrophages for Efficient Colon Cancer Therapy

Specifically Eliminating Tumor-Associated Macrophages with an Extra- and Intracellular Stepwise-Responsive Nanocarrier for Inhibiting Metastasis.

Protein-Crowned Micelles for Targeted and Synergistic Tumor-Associated Macrophage Reprogramming to Enhance Cancer Treatment.

Synergy of nanodiamond–doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells

In situ Engineering of Tumor-Associated Macrophages via a Nanodrug-Delivering-Drug (β-Elemene@Stanene) Strategy for Enhanced Cancer Chemo-Immunotherapy

A Cancer Cell Membrane Coated, Doxorubicin and Microrna Co-Encapsulated Nanoplatform for Colorectal Cancer Theranostics

Precise Delivery of Nanomedicines to M2 Macrophages by Combining "eat Me/Don't Eat Me" Signals and Its Anticancer Application.

Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms

CD163 Monoclonal Antibody Modified Polymer Prodrug Nanoparticles for Targeting Tumor-Associated Macrophages (TAMs) to Enhance Anti-Tumor Effects

Nanoparticles targeting tumor-associated macrophages: A novel anti-tumor therapy

Spatially Targeting of Tumor-Associated Macrophages and Cancer Cells for Suppression of Spontaneously Metastatic Tumor

Lipopolysaccharide-anchored macrophages hijack tumor microtube networks for selective drug transport and augmentation of antitumor effects in orthotopic lung cancer.

A Novel Nanomissile Targeting Two Biomarkers And Accurately Bombing Ctcs With Doxorubicin

Cancer-associated Fibroblast-Targeted Nanodrugs Reshape Colorectal Tumor Microenvironments to Suppress Tumor Proliferation, Metastasis and Improve Drug Penetration

Nanomaterials targeting tumor associated macrophages for cancer immunotherapy

Transformable Honeycomb-Like Nanoassemblies Of Carbon Dots For Regulated Multisite Delivery And Enhanced Antitumor Chemoimmunotherapy

Leveraging Macrophage-Mediated Cancer Immunotherapy Via a Cascading Effect Induced by a Molecularly Imprinted Nanocoordinator.

Synergistic Combination of Multistage Magnetic Guidance and Optimized Ligand Density in Targeting a Nanoplatform for Enhanced Cancer Therapy

Spatial Targeting of Tumor-Associated Macrophages and Tumor Cells with a Ph-Sensitive Cluster Nanocarrier for Cancer Chemoimmunotherapy.

Nanoparticle‐Laden Macrophages for Tumor‐Tropic Drug Delivery

Pluronic-Based Nanoparticles for Delivery of Doxorubicin to the Tumor Microenvironment by Binding to Macrophages